CAS 1000025-07-9: N-[[5-(3-chlorophényl)-3-hydroxy-2-pyridinyl]carbonyl]glycine

Vadadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is a synthetic small molecule. Its mode of action involves the inhibition of prolyl hydroxylase enzymes, which normally facilitate the degradation of hypoxia-inducible factor (HIF) under normal oxygen conditions. By stabilizing HIF, vadadustat effectively mimics a hypoxic response, leading to increased endogenous production of erythropoietin (EPO), a key hormone in red blood cell production. Vadadustat is primarily used for the management of anemia, particularly in patients with chronic kidney disease (CKD), where secondarily elevated EPO levels stimulate erythropoiesis. The stabilization of HIF also results in the upregulation of other genes associated with iron metabolism and erythropoiesis, providing a coordinated approach to correcting anemia. This pharmacological profile makes vadadustat a promising therapeutic option offering a potentially advantageous safety and efficacy profile compared to traditional erythropoiesis-stimulating agents. The continued investigation into its long-term outcomes and comparative benefits remains a significant focus within nephrology and hematology research.

Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.

Vadadustat

Applications Vadadustat is a novel HIF (Hypoxia-inducible factor) stabilizer. It provides an effective anemia treatment in nondialysis-dependent chronic kidney disease. References Pergola, P., et al.: Kidney Int., 90, 1115 (2016);